causing secondary systemic HT in cats is chronic kidney disease (CKD), followed by hyperthyroidism. 4, 5 In about 20% of cats with systemic HT, however, no underlying disease is identified and thus are classified as idiopathic. 5 The pathophysiology of systemic HT in cats is poorly understood. The renin angiotensin aldosterone system (RAAS) could play a role based on studies in small cohorts of cats with CKD and idiopathic HT and in cats with hyperthyroidism. 6, 7 Chronic kidney disease-related systemic HT is believed to be induced by the activation of the RAAS. 7, 8 Angiotensin-II is a central mediator of renal injury because of its ability to produce glomerular HT resulting in glomerular damage and activation of pro-inflammatory and profibrotic pathways. 9 , 10 Chronic RAAS activation leads to persistent systemic HT via systemic vasoconstriction, intravascular fluid expansion, and sympathetic activation, mediated by the angiotensin-II type 1 receptor (AT 1 receptor). 11 The direct inhibition of AT 1 receptors with angiotensin receptor blockers (ARBs) inhibits the activation of these receptors by multiple mediators, some of which are formed by pathways that do not involve conventional angiotensin converting enzymes (ACEs) and leave the angiotensin-II type 2 receptor (AT 2 receptors) available for activation. 12 Angiotensin-II type 2 receptors mediate beneficial actions of angiotensin-II (AT-II) such as vasodilation and natriuresis. 13 The underlying mechanisms of systemic HT secondary to hyperthyroidism in cats remain to be determined, although dysfunction of the RAAS is suspected. 7 Although the RAAS is implicated in cats with systemic HT of various cause, some cats do appear to have low renin HT. In human medicine, inhibition of the RAAS appears to benefit patients with low renin HT. 14 Drugs that are used to treat systemic HT in cats include calcium channel blockers, angiotensin converting enzyme inhibitors (ACEi), beta-blockers, and diuretics. 8, 15, 16 However, so far, only the calcium channel blocker amlodipine lowers adequately systemic blood pressure, 3, 17, 18 which is accompanied by activation of the RAAS system. 6 Telmisartan is an AT-II receptor antagonist which selectively binds to the AT 1 receptor and thus inhibits the pro-hypertensive effects of AT-II including vasoconstriction, sodium chloride retention, vascular and cardiac muscle hypertrophy, and pro-fibrotic effects in the kidney and cardiovascular systems. 19 In human medicine, telmisartan is authorized for the control of systemic HT and cardiovascular prevention. [19] [20] [21] In experimental models, telmisartan effectively inhibits angiotensin-induced pressure responses of cats at doses of 1-3 mg/kg. 22 In cats with CKD, telmisartan at the dose of 1 mg/kg PO q24h
proved to be an effective antiproteinuric drug, significantly reducing proteinuria relative to baseline at all assessment points. 23 The goal of the present field study was to evaluate the efficacy and safety of telmisartan at reducing systemic HT in cats.
| MATERIALS AND METHODS

| Animals
Client-owned, adult, cats presented during routine clinical practice at the participating 51 centers from Germany, France, United Kingdom, Netherlands, and Switzerland were screened for systemic HT. Cats of either sex were eligible for inclusion if owner informed consent was given and the cats complied with all inclusion and exclusion criteria. Cats were ineligible for inclusion if they had received medications known to affect blood pressure, such as ACEi, ARBs, calcium channel blockers, or diuretics <14 days before start of treatment.
Cats were excluded if SABP was >200 mmHg at both screening visits, SAPB measurements were highly variable in the individual cat with differences of >20% on 3 consecutive blood pressure measurements at 1 visit, or they had acute or severe TOD, total T4 concentration > 60 nmol/L, were pregnant, or were lactating. Acute or severe TOD was defined by the presence of retinopathy/choroidopathy (acute blindness, retinal detachment, or retinal/vitreal hemorrhage), signs of hypertensive encephalopathy such as seizures, or other centrally localizing neurological signs of acute onset. Furthermore, cats were excluded, if azotemia was related to acute kidney injury or decompensated CKD or to known pre-or post-renal factors or to considerable risk for the cat not to complete the entire study period. Furthermore, cats with confirmed or suspected concomitant diseases such as diabetes mellitus, congestive heart failure, or neoplasia were ineligible.
| Study design
This multicenter prospective, randomized, double-blinded, placebocontrolled study with parallel group design was conducted according to Good Clinical Practice principles. 25 The study consisted of a 28 day efficacy phase and a subsequent 92-day extended use phase.
Physical examination, fundoscopy, and SABP measurement were performed before inclusion and on study days 14, 28, 56, 84, and 120.
Blood samples were collected in ethylenediaminetetraacetic acid and serum tubes and sent to Vet Med Labor GmbH (Germany) before the start of study and on study days 28 and 120. Urine was collected by cystocentesis and analyzed by the same laboratory before inclusion.
During the efficacy phase, cats were randomly assigned at a rate of 2 : 1 to telmisartan oral solution at a dosage of 2 mg/kg or an optical identical oral placebo once daily. This treatment dose was chosen based on the results of a previous study. 26 The randomization was performed using a covariate-adaptive randomization procedure with the focus on achieving an approximate ratio of 2 : 1 for telmisartan and placebo with respect to the 2 stratifying factors "classification of hypertension" and "study site," while also including a random component. 27 In every randomization step, the current imbalance from the expected 2 : 1 ratio was determined for each of the stratifying factors.
This allocation scheme ensured an approximate treatment ratio of 2 : 1 for each site separately and for each HT class across sites. After Day 28, treatment was unmasked and cats treated with telmisartan were allowed to enter the extended use phase. During this phase, the telmisartan dose could be decreased at the discretion of the investigator if the cat's SABP was <160 mmHg. The target SABP range was defined as 120-160 mmHg. Cats with SABP >200 mmHg were removed from the study and treated at the discretion of the attending clinician.
Routine treatments with no known impact on systemic HT (eg, vaccinations, antiparasitic drugs) were allowed during the study. Antiinflammatory drug treatment during the study was only permitted as short-term (<14 days) treatment. The protocol was prepared in consultation with independent experts and approved by local authorities, when required. All adverse events (AEs) were reported in accordance with local regulations.
| Statistical methods
A composite primary efficacy end point was defined a priori for the evaluation of telmisartan efficacy. The first co-primary end point was the difference in mean SABP change from baseline to Day 14 between the telmisartan and placebo treatment group, which was tested by a 2-sided 2-sample Student's t test with alpha = 0.05 (SAS software, Version 9.4; SAS Institute, Cary, North Carolina). The null hypothesis of no difference in mean SABP change between telmisartan and placebo after 14 days treatment was tested for the per protocol set (PPS) population. The second co-primary end point was clinically relevant mean SABP reduction for telmisartan, defined by a mean SABP decrease >20 mmHg between baseline SABP and SABP on study day 28. The ACVIM consensus statement defined the goal of systemic HT treatment of cats as achieving a reduction in the category of risk for future TOD. 4 The primary end point criterion that the mean SABP reduction should be ≥20 mmHg fulfilled this goal completely, because it assured that the risk of the included cat group for future TOD is reduced by at least 1 category on Day 28 compared to baseline after the ACVIM HT consensus statement.
For animals excluded from the study on study day 14 or thereafter due to SABP >200 mmHg or development of acute or severe TOD, missing SABP data were imputed on the subsequent visits using the last observation carried forward (LOCF) method, imputing the last observed SABP from the same animal.
A sample size calculation was performed by simulations using the SAS software (version 9.3, SAS Institute) and calculated as the number of animals required to successfully achieve both co-primary end points. The original assumptions of the sample size calculation were reviewed within an a priori planned interim analysis. In the latter, only the required number of animals was provided to prevent any potential unblinding. This sample size calculation indicated that 294 cats were required to evaluate the efficacy of telmisartan over placebo (ratio telmisartan/placebo 2 : 1) with alpha = 0.05, a power of 80%, 10% dropouts without LOCF data available, and using the following assumptions for effect and variability estimates: mean telmisartan The efficacy of study treatments was assessed on the basis of the PPS population. This group comprised all study animals having reached at least study day 14. Cases of relevant deviations from the protocol (eg, enrollment of cat although exclusion criterion was fulfilled) and cases not subjected to all the relevant assessments (eg, study protocol was not followed due to owner's noncompliance) were not included in the PPS. The intention to treat (ITT) population included cats that had at least 1 documented dose of telmisartan or placebo administered, at least 1 analyzable data parameter available, and major entry criteria were satisfied. The safety (SAF) population included all cats that had received at least 1 dose of telmisartan or placebo. The SAF population was used for the analysis of AEs, which were reported by the participating veterinarians and for the analysis of clinicopathologic data. Incidence of AEs was summarized descriptively by treatment groups and the proportions of cats that experienced at least 1 AE were compared between groups by a chisquare test.
| RESULTS
Out of 818 documented screened cats, a total of 294 cats were enrolled, on average 6 cats per site, and included in the SAF data set (Figure 1 ). Of those, 285 formed the ITT population and 262 cats comprised the PPS. The end of the placebo controlled study phase (Day 28) was reached by 165 telmisartan-treated cats and 87 placebo-treated cats. One placebo-and 2 telmisartan-treated cats were removed from the study before Day 28 due to SABP >200 mmHg according to the study protocol. For the efficacy analysis, however, their data were included using the LOCF method. By the end of an additional 2nd phase (Day 120) additional 21 cats had discontinued the study, due to lost to follow-up (4 cats), AEs (3 cats: renal failure in 1 cat; hypersalivation in 1 cat; anorexia, diarrhea, vomiting, and renal failure in 1 cat), or withdrawal of owner consent (9 cats). Six cats were removed due to SABP >200 mmHg in this 2nd phase of the study.
Age, body weight, breed distribution, causes of systemic HT, and baseline SABP were similar in both groups (Table 1) . Males and females were not evenly distributed in both groups with more males in the placebo group. However, the mean reduction of SABP after 28 days was comparable between the neutered males and females in both treatment groups.
The primary analysis showed a significant difference in mean SABP change between the telmisartan and placebo groups on Day 14 (P < .001) and a clinically relevant mean telmisartan SABP reduction of 24.6 mmHg on Day 28; hence, both co-primary end points
Assessed for eligibility (n = 818)
Screening failure* (n = 524):
• SABP less than 160 (n=197),
• Total T4 greater than 60 (n=63),
• No signature of Owner Consent (n=33),
• Cat has concomitant disease (n=12),
• SABP greater than 200 (n=7)
• Cat has azotemia due to renal disease (n=6),
• Cat has TOD (n=6), Removal from SAF due to:
• No analyzable data parameter is available after randomization (n=3), • Major entry criterion was not met (n=1) PPS Population (n=174):
Removal from ITT due to:
• No D14 visit (n=4),
• Inclusion criteria not met (n=1),
• Exclusion criteria was met (n=5),
• Treatment non compliance (n=5) PPS Population (n=88):
• Exclusion criteria was met (n=2),
• Treatment non compliance (n=6)
ITT Population (n=189):
Removal from SAF due to:
• No study drug administration documented (n=1),
• No analyzable data parameter is available after randomization (n=3), • Major entry criterion was not met (n=1)
Reason for cat removal from PPS population in efficacy phase:
• Owner non compliance (n=3)
• Difficulty with study drug administration (n=3)
• Euthanasia due to lack of eating and drinking (n=1) • Adverse event (hemorrhagic gastroenteritis, dyspnoea) (n=2)
• Owner non compliance (n=1) FIGURE 1 Participant flow were successfully achieved (Table 2, Figure 2 ). In order to check the primary analysis result for robustness, the testing procedure was reperformed for the ITT population as well. Both co-primary end points were achieved in the ITT population with similar results ( In the 2nd phase of the study, the mean decrease in SABP from baseline in the telmisartan group was persistent over time on Days 56, 84, and 120 (Tables 3 and 4 ).
The mean reduction in SABP in the telmisartan group in the severely hypertensive category (≥180 mmHg) was comparable to those with moderate systemic HT (160-179 mmHg) ( Table 5 ).
The starting telmisartan dose of 2 mg/kg PO q24 was administered to all cats in the efficacy phase of the study. The majority of cats were continued on this dose (112/143 cats; 78%), whereas some cats (31/143 cats; 22%) were down titrated to a dose of 1.5 mg/kg or lower.
No clinically relevant changes in routine hematological and biochemical parameters at study end compared to baseline were observed ( Table 6 ).
The proportion of cats with at least 1 AE during the efficacy phase was similar in both groups (telmisartan: 30% [58/194 cats], placebo: 29% [29/100 cats], P = .89). Overall, the incidence of cats with at least 1 AE was low in the efficacy phase ( 
| DISCUSSION
In this large clinical field study, it was demonstrated that telmisartan lowers the mean SABP in cats with systemic HT compared to placebo, controls SABP over time and is well tolerated.
In the cats of this study, representing patients as seen by veterinarians in daily practice, mean reduction of SABP was significantly different between the telmisartan and placebo groups on Day 14 and the mean reduction in response to telmisartan was deemed clinically relevant as the mean SABP decreased by more than 20 mmHg in the telmisartan group by Day 28. The effect on lowering mean SABP and the proportion of cats with SABP <150 mmHg to minimize TOD 4, 28 increased between Days 14 and 28 without an increase of the dose, and the antihypertensive effect was persistent over the 120-day FIGURE 2 Mean (95% confidence interval of the mean) changes from baseline in systolic arterial blood pressure during the blinded efficacy phase (per protocol set population) study duration. This observation was reconfirmed by the results obtained after repeating the analysis without those cats that dropped out during the study with a high blood pressure. This finding is similar to those in human patients, in which it is known that after the first dose of telmisartan, the antihypertensive activity gradually becomes evident within 3 hours, and the maximum reduction in blood pressure is generally attained 4-8 weeks after the start of treatment and is sustained during long-term treatment. 21 The observed mean SABP reduction in the telmisartan group was in line with the assumption based on the interim analysis. The assumption regarding the mean SABP change in the placebo group based on the interim analysis was somewhat higher compared to the result of the study. This discrepancy in placebo effect estimates might be related to the lower number of available cats in the placebo group at the time the interim analysis was performed due to the 2 : 1 randomization ratio.
Although, the role of the RAAS in systemic HT of cats is not fully understood, the results of the present study suggest that activation of the RAAS might be involved in the pathogenesis, as systemic HT could be successfully controlled, independent of the underlying disease or idiopathic HT. The relative lack of efficacy of ACE inhibitors (ACEis) in treating systemic HT in cats observed by others 8, 15, 16, 29 could be explained by the use of an inadequate dosage, inadequate conversion of angiotensinogen into AT 1 receptor agonists without the involvement of conventional ACE. An alternative explanation might be the fact that ARBs leave the AT2 receptor effects of AT-II intact.
The mean SABP decrease in placebo-treated cats of around 10 mmHg on Day 14, which persisted until Day 28, had been also observed in a previous study. 18 This might be due to a training effect regarding the procedure of measuring blood pressure, respectively the fading of a white coat effect over time. 30 Another potential hypothesis, although less likely, might be a true placebo effect, resulting from either how the veterinarian approached the blood pressure measurement process or how the owners treated the cat. Whatever the reason, this finding illustrates the importance of including a placebo group for blood pressure trials in veterinary medicine.
Telmisartan at a starting dose of 2 mg/kg PO q24h was well tolerated and safe to use in this study of cats with HT, as was found previously when telmisartan was used at half this dose in a group of elderly cats with CKD. 23 Generally medications targeting the RAAS, such as ACEis, or ARBs might induce a decline in glomerular filtration rate particularly in cases with late stage kidney disease or in dehydrated animals with CKD and regular monitoring according to good clinical practice is deemed appropriate. However, there was no increase in mean serum creatinine in cats treated with telmisartan in this study, even in the subgroup of cats with IRIS stage 2 and 3 CKD.
There are some differences between the present study and the previous randomized controlled clinical trial involving the use of amlodipine in hypertensive cats that are worthwhile mentioning. One is that SABP in the present study was measured by Doppler compared to high-definition oscillometry in a previous study. 18 The Doppler methodology was chosen as at the start of the study it was the most commonly used method by practitioners and none of the available methods had been fully validated according to the ACVIM consensus statement criteria. Another difference in the studies was the criteria to define a responder. In the present study, the mean SABP reduction in the telmisartan group had to be both, significantly different compared to placebo at Day 14 and to be higher than 20 mmHg compared to baseline at Day 28. The criteria in a previous study were decrease of SABP to <150 mmHg or decrease from baseline of at least 15%.
18
In the previous study, the dosage of amlodipine was doubled at Day 14 in 54% of the cats due to nonresponse at the starting dose, which was not allowed in the present study; higher doses of telmisartan could have increased the number of responders in the present study.
Another difference is that cats receiving ACEi were ineligible for inclusion in the present study, whereas in a previous study 15.6% of the enrolled cats were on concomitant ACEi treatment. 18 Common causes of systemic HT in the present study were CKD, hyperthyroidism, and a combination of the 2. This was not unexpected, because these are the most common reported causes of systemic HT in cats, and therefore such cats are specifically screened. 4 However, the percentage of cats with idiopathic HT seemed to be relatively high in comparison to previous publications reporting 17%-23% of the investigated cats having idiopathic HT. 5, 31, 32 One explanation for this finding might be the definitions of CKD and hyperthyroidism. In the present study, CKD was diagnosed if the cat had urine specific gravity below 1.035 combined with plasma creatinine above 1.6 mg/dL or abnormal kidneys on palpation or on ultrasound or on radiographic examination. Euthyroidism was defined as serum total T4 < 60 μmol/L; however, hyperthyroidism might already be present at a T4 > 40 μmol/L. 7 Another reason might be whitecoat HT contributing to the placebo effect, which might be present in an unknown number of cats enrolled in this study. Furthermore, there are relatively few studies in the literature documenting the prevalence of HT in cats, and most publications are biased toward screening only those populations of cats that are deemed to be at risk. In the present study, by contrast, not only cats at risk of HT because of the underlying concomitant diseases were screened but a more general cat population. Although, there might have been differences among the selection of screened cats at each study center, the high number of participating study sites resulted in a overall group of screened cats, which reflected a more general cat population. Thus, it is entirely possible that more idiopathic hypertensive cats were recruited to the present study because cats registered with primary care practitioners were screened more widely for HT than in previous studies. Even if the percentage of idiopathic HT is overestimated in this study, it nevertheless supports previous reports in which idiopathic HT was a common finding in cats. A limitation of the present study was the exclusion of cats with SABP above 200 mmHg (ie, cats with most severe systemic HT and highest risk of TOD) as it was considered unethical to enroll such cats where the risk of TOD appears to be extremely high into a placebocontrolled study. In accordance, the primary end point criterion that the mean SABP reduction should be ≥20 mmHg would not necessarily lead to a reduction in the category of risk for future TOD if cats with SABP above 200 mmHg would have been included. Nevertheless, it is expected that telmisartan would efficiently lower SABP also in these cats based on the observation in the present study as SABP was as effectively controlled as in cats with less severe systemic HT. In a recent published case report of a severely hypertensive cat, telmisartan as monotherapy effectively controlled blood pressure, whereas benazepril as monotherapy was unsuccessful after amlodipine had to be withdrawn due to development of gingival hyperplasia. 33 Further limitations such as excluding cats with severe CKD from the study, the relatively high number of cats classified as idiopathic HT or whitecoat HT contributing to the placebo effect, have been discussed in more detail above.
Future studies are warranted to determine the optimal dose required to meet the target posttreatment blood pressure in cats with pretreatment blood pressure in excess of 200 mmHg.
In summary, telmisartan oral solution at 2 mg/kg q24h proved to lower SABP by a clinically relevant magnitude and duration in the absence of significant treatment-related AEs. Thus, telmisartan is a valuable option for the treatment of systemic HT in cats.
